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Abstract
Background: Antigen-based (as opposed to whole organism) vaccines are actively being pursued for numerous indications.
Even though different formulations may produce similar levels of total antigen-specific antibody, the composition of the
antibody response can be quite distinct resulting in different levels of therapeutic activity.
Methodology/Principal Findings: Using plasmid-based immunization against the proto-oncogene HER-2 as a model, we
have demonstrated that affinity-selected epitope mimetics (mimotopes) can provide a defined signature of a polyclonal
antibody response. Further, using novel computer algorithms that we have developed, these mimotopes can be used to
predict epitope targets.
Conclusions/Significance: By combining our novel strategy with existing methods of epitope prediction based on physical
properties of an individual protein, we believe that this method offers a robust method for characterizing the breadth of
epitope-specificity within a specific polyserum. This strategy is useful as a tool for monitoring immunity following
vaccination and can also be used to define relevant epitopes for the creation of novel vaccines.
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Introduction
Proper characterization of the antibody response produced by
vaccination is dependent upon the ability to characterize the
specific target epitopes that are recognized by the polyserum. As
an example, the HER-2 protein is over-expressed in ,30% of
breast cancer patients and is associated with poor prognosis [1,2]
making HER-2 an attractive target for the development of
antigen-specific cancer vaccines. Caution is needed, however, as
only antibodies to specific epitopes can suppress tumor growth
[2,3] while others actually stimulate growth [4]. As such,
measurement of total levels of antigen-specific antibody is not an
appropriate measure of vaccine activity since not all antibodies
would be able to provide therapeutic effect. Rather, it is necessary
to employ assays that permit quantification of antibodies to specific
functional epitopes to adequately monitor B cell immunity.
Given the broad range of potential epitopes within a protein,
characterizing the breadth of epitopes recognized by a particular
polyclonal response is quite challenging. While it may be possible to
monitor antibodies directed against linear epitopes using synthetic
peptides, the majority of antibody responses [5] are directed at
structural epitopes which are difficult to recapitulate with synthetic
peptides. We have been investigating methods that employ affinity-
selection of random peptides to provide an unbiased approach to
epitopecharacterization.Wehavepreviouslydemonstrated thatthis
method can be used to characterize the target epitopes of
monoclonal antibodies [6,7,8,9,10,11,12,13,14] and, more recently,
we have also applied this technology to polyclonal serum [15].
Manipulation and identification of random peptides is facilitated by
the use of phage-display [16] where the random peptides presented
on the phage surface serve as peptidomimetics of conformational
and discontinuous antibody epitopes [17,18] referred to commonly
as ‘‘mimotopes’’. Isolation of specific mimotopes is accomplished
throughaffinityselectionwhereantibodies ofinterest arefirst bound
to a solid matrix and subsequently adsorbed to the phage library
expressing the mimotopes. Iterative washing and adsorption steps
allows for enrichment of phage carrying mimotopes which are
specific forthebound antibodies. Themimotope sequencesarethen
analyzed and assigned a location on the target protein using
algorithms that we have designed [9,15].
In the current manuscript, we have applied this method to
characterize the specificity of polyclonal responses produced
following immunization against a specific antigen. We have
chosen HER-2 as a model antigen. As stated previously, this
protein is an interesting target for vaccine development but the
diverse biological effects of individual HER-2 antibodies (either
stimulatory or inhibitory) necessitate careful analysis of the
polyclonal repertoire following immunization. Epitope selection
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structure within the vaccine inoculum. As such, the diversity of the
polyclonal antibody response is a direct reflection of the specific
vaccine formulation. To determine the utility of our mimotope
technology for characterizing the epitope diversity of different
polysera directed against the same protein, we examined the
binding properties and epitope specificity of mouse polyserum
against HER-2 generated by different vaccine inocula.
Results and Discussion
The composition of polyclonal responses generated in
response to rat HER-2 is dependent upon the method of
immunization and structure of the antigen
Mice were immunized against rat HER-2 using different
strategies to determine how the method of exposure influences
the antibody response. We chose to employ a xenoantigen, rat
HER-2, rather than the murine homolog because our previous
experience has determined that xenoantigens are more immuno-
genic than native antigens and yield cross-reactive immune
effectors that recognize both the native and xenoantigen
[19,20,21]. We opted to employ plasmid vaccines expressing
different forms of HER-2 since this method has been shown to be
highly effective in mice [22,23,24]. Previous work has found that
similar titers of antibodies against the HER-2 extracellular domain
(ECD) were evoked by immunization with plasmids expressing
either the soluble ECD or full length HER-2 [24]. Given the
likelihood that soluble ECD and membrane-bound ECD would
adopt distinct structures and give rise to a different spectrum of
antibodies, we sought to compare the properties of polysera
produced by plasmid immunization with the 2 forms of HER-2.
To this end, mice were immunized with plasmids expressing either
the full length protein (HER-2FL) or the soluble extracellular
domain only (HER-2ECD). We also observed that mice inoculated
with TUBO tumors, which express rat HER-2, developed high
titer antibodies against rat HER-2 (data not shown). Since the
structure of the full-length protein on tumor cells may also be
different than full-length protein expressed following plasmid
vaccination, we included this polyserum in our analysis, as well
(HER-2TUBO).
All 3 methods yielded similar titers of antibody as determined by
ELISA (Fig. 1A). Using Western blot analysis, we observed that
the polyserum generated in response to HER-2ECD recognized
both native and denatured forms of HER-2 equally well
(Figure 1B). By contrast, binding of HER-2 by HER-2FL and
HER-2TUBO polyserum was completely ablated by denaturation
(Figure 1B). Since it appeared that the antibodies generated in
mice exposed to full-length HER-2, either through plasmid
vaccination or exposure to tumor cells, have distinct specificity
relative to the antibodies produced in response to HER-2ECD,w e
examined the ability of the sera to recognize native HER-2
expressed on the surface of TUBO cells. For this experiment,
TUBO cells were coated with various dilutions of serum and the
quantity of bound antibody was determined by flow cytometry.
Unfortunately, we could not employ this method to study
polyserum produced by TUBO cells themselves because we could
not distinguish HER-2 specific antibody from other TUBO-
specific antibodies. Nonetheless, these data demonstrate that
although the HER-2ECD and HER-2FL polysera exhibit compa-
rable titers of anti-HER-2 antibody by ELISA (Figure 1A), the
HER-2FL polyserum had markedly enhanced capacity to bind the
native protein (Figure 1C), suggesting that the polyserum
produced by HER-2FL may be more specific for the native form
of the protein. Given the observation that the HER-2ECD
polyserum was less sensitive to protein structure, we hypothesized
that this polyserum would also prove to be more cross-reactive.
Indeed, when the various polysera were tested for cross-reactivity
by Western blot, to another form of HER-2 (human HER-2), the
HER-2ECD polyserum revealed some cross-reactivity whereas the
HER-2FL and the HER-2TUBO showed no binding to the human
protein (Figure 1 D). Thus, although all 3 polyserum exhibit
similar titers of anti-HER-2 antibodies by ELISA using native
protein, it is clear that each polyserum is composed of a discrete
combination of individual antibody specificities.
Differential polyserum compostion correlates with
impact on tumor growth in vitro
To gain further insight into possible differences in the polysera,
we tested whether the anti-HER-2 antibodies would suppress
TUBO cell proliferation in vitro. TUBO cells were grown for 2
weeks in the presence of IgG purified from the various polysera
(25 mg/ml final). Only IgG purified from the HER-2FL serum
suppressed tumor cell growth whereas the other sera had no effect
(Figure 1E; p,0.01 based on ANOVA and post-hoc Tukey test).
These results again demonstrate that the polyserum produced by
the 3 immunization methods have different functional properties.
Notably, even though both sera produced in response to full-length
protein (HER-2FL and HER-2TUBO) display similar dependence
upon protein structure for binding, the functional effects of these
polysera appear to be distinct. This difference may reflect
differential abundance of inhibitory and activating antibodies.
Characterization of eptiope specificity within the anti-
HER-2 polysera using affinity-selected random peptides
Characterization of epitope specificity for antibodies can be
quite challenging, particularly in the case of structural epitopes.
Since binding of both HER-2FL and HER-2TUBO sera to
recombinant HER-2 is abrogated when the protein is denatured,
it would appear that the epitopes recognized by these sera are
largely conformational. Therefore, to characterize the epitope-
specificity of these sera, we opted to employ a mimotope-based
strategy where random circularized peptides displayed on
recombinant phage are affinity-selected using specific polyserum
and a computer algorithm is employed for epitope prediction
based on the sequence of the selected mimotopes [9,15]. To
facilitate the manipulation and identification of these random
peptides, we have employed a phage-display method where
random 10-mer circularized peptides are expressed on N-terminus
of the phage major coat protein. Since unrelated antibodies
present in mouse serum can confound our analysis, the phage
library was adsorbed to naı ¨ve mouse serum prior to further
analysis to remove all phages that were reactive with general
mouse antibodies. Likewise, anti-phage antibodies present in
mouse serum would also complicate interpretation, so the sera to
be tested was adsorbed to immobilized wild type phage fd-tet [25]
to remove phage-specific antibodies. Phage bearing specific
mimotopes were enriched through iterative immunoaffinity
selection steps on immobilized anti-mouse IgG. Specific phages
were defined as those which bound to serum from immunized
mice but not to serum from naı ¨ve mice. The sequences of the
specific mimotopes selected through iterative rounds of screening
are presented in Table 1. Interestingly, we did not find any
common mimotopes in the collection of sequences selected by
each individual polyserum suggesting that each serum is composed
of distinct antibodies. It is also notable that we only uncovered a
limited set of phages with HER-2TUBO serum, suggesting that this
polyserum has a limited range of specificity.
Epitope Mapping with Mimotopes
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phages, representative phages from each collection were hybrid-
ized with each of the 3 polysera using dot blot. In each case, the
selected phage hybridized best with the sera used for the affinity
purification (Figure 2). Even though we did not isolate mimotopes
using HER-2FL serum that matched the sequence of the
mimotopes selected with HER-2ECD serum, we did find 2 phage
isolated with HER-2FL that could be recognized by both sera (FL.6
and FL.23) (Figure 2A). Notably, phage FL.23 was bound by all 3
sera. In the case of the phage isolated with HER-2ECD serum,
although we observed low-level cross-reactivity with HER-2FL
serum, we observed no cross-reactivity with HER-2TUBO serum
(Figure 2B). With regard to the phage selected by HER-2TUBO
serum, comparable, low-level cross-reactivity was seen with both
HER-2FL and HER-2ECD (Figure 2C).
Given the limited cross-reactivity between the affinity-selected
phages, it appeared as though the selected phage may reflect a
molecular ‘‘signature’’ of the polyclonal specificity. One way to
describe such a ‘‘signature’’ would be the analysis of the specific
amino acid residues within each collection of phages. Each
collection of phages was dominated by a distinct set of amino acid
residues (Table 2) resulting in a distinct hierarchy of amino acid
frequency with the various collections. Furthermore, when we
examined the frequency of specific amino acid pairs, which reflects
the minimal homology elements that are employed by the
computer algorithm for epitope prediction [9,11], we found that
the majority of generalized pairs were unique to each collection
(Table 3, bold letters) and only a few pairs were found in more
than 1 mimotope collection (Table 3, italicized). These results
demonstrate that the phage selected through our affinity-
purification method represent a ‘‘signature’’ of the respective
polyserum used for purification.
Affinity-selected phage can be used to predict epitopes
targets of the polyserum
Of interest, we also sought to determine whether the affinity-
selected mimotopes could be used to elucidate the epitopes
recognized by the polyserum. To attribute the mimotope
sequences to specific epitopes on the protein, we used our
novel computer algorithm [9] which categorizes mimotopes
based on minimal homologies (i.e. neighbouring amino acids)
into clusters defined by the position of these minimal
homologies on the folded protein. These clusters represent
hypothetical epitopes. As a result of cluster analysis performed
using stringent conditions where we only included amino acid
pairs determined to be significant based on their actual
occurrence compared to the estimated random occurrence
[11], a numbers of distinct clusters were found on the surface
of the protein (Figure 3, Table 4). Six epitopes were predicted
for the HER-2ECD polyserum (ECD#1–ECD#6; Figure 3A;
Table 4), six epitopes were predicted for the HER-2FL serum
(FL#1–FL#6; Figure 3B; Table 4) and a single epitope was
predicted for HER-2TUBO serum (TUBO#1).
To determine whether the epitopes predicted by our affinity-
selected mimotopes are consistent with regions predicted to be
immunogenic, we employed the DiscoTope computer algorithm
Figure 1. Antigen structure influences the composition of the polyclonal response. A. ELISA plate wells were coated with recombinant rat
ECD and reacted with serial dilutions of mouse sera. B. Recombinant extracellular domain (ECD) of rat HER-2 was treated (reduced protein) or not
(native protein) with b-mercaptoethanol and run in 10% SDS PAGE, transferred onto nitrocellulose membrane and probed with mouse sera diluted
1:1000. C. 10
6 Tubo cells over-expressing rat HER-2 were reacted with serial dilutions of mouse sera, probed with anti-mouse antibody conjugated
with PE and fluorescence intensity was measured by flow cytometry. Each point is reflective of at least 10 000 events. D. Recombinant extracellular
domain of rat HER-2 or human HER-2 were run in 10% SDS PAGE, transferred onto nitrocellulose membrane and probed with mouse sera diluted
1:1000 or anti-HER-2 antibody. E. 500 TUBO cells were plated into 96 well plate in DMEM medium supplemented with 5% FBS and incubated 1–2
weeks in the presence of IgGs purified from mouse sera at a final concentration of 25 mg/ml.. The cell proliferation was measured according to
manufacturer instruction by CellTiter 96H Aqueous Non-Radioactive Cell Proliferation Assay. The error bars reflect the mean+/2sem for 4 samples.
These data represent the results of pooled serum from 5 vaccinated mice per group. Each experiment was replicated at least 3 times and
representative results are shown.
doi:10.1371/journal.pone.0005309.g001
Table 1. Mimotope sequences of affinity-selected phage.
HER-2ECD
a mimotopes HER-2FL mimotopes HER-2TUBO mimotopes
Phage
Mimotope
sequence Phage
Mimotope
sequence Phage
Mimotope
sequence
ECD.1 KAEERFHEVR FL.1 NWSIAGD TUBO.1 TYSGRAACGV
ECD.2 WNIFQSLSSP FL.2 SRGDTEP TUBO.2 SASMPFPANE
ECD.3 RVAATAAREE FL.3 TSDSWQR TUBO.3 SKPKYEKPSQ
ECD.4 TPEPLEEAAS FL.4 PKTEVPQ TUBO.4 EVTTEHVEAN
ECD.5 DHVFKRPQPS FL.5 DDFSPPR TUBO.5 RSHERHPPSP
ECD.6 ETCVEKNEAD FL.6 EWYTPQG TUBO.6 DDELHSGTSY
ECD.7 WRRDGC FL.7 SRCDLDEKGC TUBO.7 SPPAFSHPMQ
ECD.8 YMDPHTQREA FL.8 PRCKHNQKKC TUBO.8 VNTQGPNSIA
ECD.9 EPVRDNCAPS FL.9 AGACKRMREF
ECD.10 VERDIATRPW FL.10 ATPKRTHDHD
ECD.11 ERPEIEDVCQ FL.11 TSNNRVEARA
ECD.12 QKTLNTSNAN FL.12 RTTPSGGGFK
ECD.13 VKTLNTSNAN FL.13 DGWYVAQ
ECD.14 RDTTMWEVNA FL.14 GGRWGES
ECD.15 WGHCSQGMIE FL.15 WYTTPGS
ECD.16 PPFDVFHNPM FL.16 SGWYTPV
ECD.17 DTHAGMHSPT FL.17 AKDEQPM
ECD.18 RMPHHDPQLM FL.18 GWYVSSP
ECD.19 TQNLMQMQHA FL.19 PSEGQSE
ECD.20 SPFMLMHGEH FL.20 GTAGGEITEH
ECD.21 TCQAGRESMHNPFL.21
FYSSMFWAVGEQ
ECD.22 WETMHNPGTP FL.22 LQEFPGDQLV
ECD.23 DALNMHEGRP FL.23 LSTRLWIPAW
ECD.24 SKLETTMHSP FL.24 KTTTWPSTPT
ECD.25 LGGMDSMHSP FL.25 MWASVNKMA
ECD.26 NTAHSDMHSP FL.26 PPPLLAGDPK
ECD.27 MAQMHEPVRS FL.27 AVNQCTTVLA
ECD.28 NTAHSDMHSP FL.28 GTAGGEITEHE
ECD.29 LPQHNMMHDP
ECD.30 PSNYSAMHAP
ECD.31 RCETHFNMHEPY
aPolyserum used for mimotope isolation.
doi:10.1371/journal.pone.0005309.t001
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(Figure 4A and Table 5). Regions predicted to be highly
immunogenic are shown in red and regions predicted to be
moderately immunogenic are shown in yellow. Strikingly, most of
the epitopes predicted by our method mapped to regions predicted
to be immunogenic based on independent criteria (Figure 4A)
which offers additional confidence in the epitopes predicted by our
method.
The C-terminus of the HER-2 ECD was predicted to be
strongly immunogenic by DiscoTope, yet none of the polyserum
mapped to this site. Interestingly, this site exhibits 100% homology
between mouse and rat proteins (Figure 4B). In general, the cluster
analysis indicates that antibody responses are directed against
epitopes on rat HER-2 where there are differences between rat
and mouse sequences. Clusters ECD#1 and FL#1 are both
located in a similar region of domain 1 close to N103 (this residue
is a putative glycosylation site in mouse HER-2 but not in rat
Figure 2. Limited cross-reactivity between phage selected with different polysera. Selected phage were immobilized onto nitrocellulose
membranes and reacted with three different sera overnight at 4uC (HER-2FL – serum prepared from mice immunized with full-length HER-2; HER-2ECD
– serum prepared from mice immunized with soluble protein; HER-2TUBO – serum from tumor bearing mice). Bound antibodies were detected with
goat anti-mouse IgG HRP conjugated antibody and the signals were developed by ECL. A. phages selected with HER-2FLserum, B. phages selected
with HER-2ECD-serum, C. phages selected with HER-2TUBO -serum).
doi:10.1371/journal.pone.0005309.g002
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in the rate protein). Common clusters ECD#3 and FL#3 are
located within domain 3 around replacements of D363 for N and
Q375 for H in the mouse protein. Cluster FL#4 is located on
domains 1 and 3 close to replacement of R71 for H and close to
cluster ECD#4 (close to replacements H457 for N). Cluster
ECD#5 is located at the beginning of domain IV around
replacement of D482 for A in mouse protein. Cluster FL#2i s
located on loop 168–182 of domain 1 close to replacement of
A177 for T. Thus, similar to T cell epitopes, B cell epitopes in
xenoantigens may also be generated by specific non-conserved
amino acids within the vicinity of the epitope which enables the B
cells to overcome tolerance.
Conformational analysis reveals distinct epitopes within
similar regions
It is interesting to note that although many of these epitopes
map to similar regions of the protein, for the most part, they
involve distinct amino acid residues (Table 4). We have observed
similar outcomes using monoclonal antibodies directed against the
West Nile virus E protein [9]. The differences in epitope selection
noted in this manuscript probably reflect differences in confor-
mation of the soluble and cell-attached proteins which alter the
way the protein is bound by antigen-specific B cells. We found that
most of the clusters are located at protruding loops or b-turns
exposed on the protein surface as it was shown for many other
epitopes [26]. Of interest, epitopes ECD#3 and FL#3 overlap
and involve many, but not all, of the same residues. These 2
clusters are located at two closely positioned turns connecting two
b-strands and two anti-parallel a-helices. It is also interesting that
clusters ECD#6, FL#5 and TUBO#1 are all located within the
area of the epitope identified for pertuzumab [27], a therapeutic
antibody currently under development. The pertuzumab epitope
encompasses three loops. ECD#6 and TUBO#1 include the first
loop of the pertuzumab epitope while cluster FL#5 includes the
two adjacent loops. Although TUBO#1 overlaps with ECD#6,
these two clusters only share 3 common residues. It is also striking
that the HER-2 specific antibodies that were generated in response
to growing TUBO tumors seemed to identify only a single cluster
which is consistent with the limited number of mimotopes isolated
by affinity selection with the HER-2TUBO polyserum (Table 4). It
is also notable that overlapping clusters FL#4 and ECD#4 are
planar surfaces formed by b-sheets and located close to each other
in domain III; however FL#4 is shifted in the direction of domain
I and is actually located at the interface between domain I and
domain III.
Antibody targets are defined by physico-chemical and geomet-
rical properties such as hydrophilicity [28], chain flexibility
[29,30], surface accessibility [38] and protrusion from the surface
[31]. Changes of antigen conformation and its participation in
various complexes should lead to corresponding changes in
immune response [32,33,34]. Our results indicate that the method
of immunization has a pronounced effect on the breadth of the
antibody response against a given protein. Affinity-selected
mimotopes can be used as a tool for characterizing these
differences and providing a ‘‘signature’’ of the polyclonal response.
Using predictive tools, this signature can also be used to
characterize the specific binding sites for the antibodies which
can offer insight into their functionality. Through iterative
application of this technology in human studies of antibody-
mediated resistance, it should be possible to develop ‘‘resistance’’
signatures which would be indicative of effective vaccination.
Additionally, knowledge of mimotopes associated with specific
‘‘functional’’ domains may serve as the basis for developing
epitope-specific vaccines.
Methods
Plasmid vaccines and immunizations
The extracelluar domain of rat HER was amplified from cDNA
using the primers 59GTCGAAGCTTATGGAGCTGG-
CGGCCTGG and 59 GACTGAATTCTTAGTTGATGGGG-
CACGG and inserted into the vaccination plasmid pcDNA3.1-
002 [35] to yield prHER-2ECD. Full length rat HER-2 was
prepared by PCR amplification of full length HER-2 gene using
primers 59-GCCCGGTGACATAAATCATTGCAACTGTAG
and 59-CTACAGTTGCAATGATTTATGTCACCGGGC and
inserted into pcDNA3.1-002 to yield prHER-2FL. Balb/c mice (6–
8 weeks old) were immunized by intramuscular injection followed
by electroporation [36] with 100 mg of pHER-2ECD or pHER-2FL.
One month later, the immunization was repeated. Serum
antibodies were measured 2 weeks following the booster
immunization. All animal work described in this manuscript was
approved by the Animal Research Ethics Board of McMaster
University.
TUBO breast cancer tumor model
The TUBO cell line, kindly provided by Dr. Guido Forni
(Department of Clinical and Biological Sciences, University of
Turin, Orbassano, Italy),wasderived from a spontaneousmammary
tumor which arose in a BALB NeuT transgenic mouse expressing
Table 2. Occurrence of statistically significant amino acids
within mimotope collections.
HER-2ECD
a
mimotopes HER-2FL mimotopes HER-2TUBO mimotopes
Residue Frequency
b Residue Frequency Residue Frequency
Glu 10.07% Gly 10.29% Ser 15.00%
Pro 9.06% Thr 9.88% Pro 13.75%
Ser 8.05% Pro 9.05% Glu 8.75%
Ala 7.72% Ser 8.23% Ala 8.75%
Arg 7.38% Ala 7.00% His 6.25%
Thr 7.05% Glu 7.00% Thr 6.25%
His 6.38% Arg 5.35% Gly 5.00%
Asn 6.38% Asp 5.35% Asn 5.00%
Met 5.70% Trp 5.35% Val 5.00%
Asp 4.36% Lys 4.94% Arg 3.75%
Gly 4.03% Gln 4.53% Tyr 3.75%
Cys 3.36% Val 4.12% Gln 3.75%
Val 3.69% Leu 3.29% Lys 3.75%
Gln 3.69% Asn 2.47% Phe 2.50%
Leu 3.02% Cys 2.47% Met 2.50%
Trp 3.02% Phe 2.47% Asp 2.50%
Lys 2.01% Tyr 2.47% Cys 1.25%
Tyr 2.01% His 2.06% Ile 1.25%
Phe 1.68% Met 2.06% Leu 1.25%
Ile 1.34% Ile 1.65%
aPolyserum used for mimotope isolation.
bThe frequency was determined as: (# specific residues/total # of residues in
the collection) 6100.
doi:10.1371/journal.pone.0005309.t002
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BALB/cmiceand give riseto tumors whichare histologicallysimilar
to those in BALB NeuT mice. 10
6 TUBO cells were injected
subcutaneously into Balb/c mice and the recipients were monitored
for tumor growth. For the experiments described in our manuscript,
serum was obtained from peripheral blood isolated one month after
tumor cell inoculation.
Proliferation assay
500 TUBO cells were plated into a 96 well plate in DMEM
medium supplemented with 5% FBS and incubated for 1–2 weeks
in the presence of serum IgGs [purified on Protein G-Sepharose
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden)] diluted at
final concentration of 25 mg/ml. Cell proliferation was measured
using the CellTiter 96H Aqueous Non-Radioactive Cell Prolifer-
ation Assay (Promega, Madison, WI, USA) according to the
manufacturer’s instructions.
Production of recombinant HER-2
Recombinant HER-2 was used for Western blot and ELISA. To
provide a source of recombinant HER-2, the extracellular
domains (without the transmembrane domain) of rat and human
HER-2 were subcloned into pcDNA3.1-002 [35] to yield prHER-
2ECD and phHER-2ECD. The plasmids were subsequently
transfected into 293T cells using Lipofectamine2000 (InVitrogen).
Supernatants were collected and the samples were concentrated
using a Vivaspin 50000 column (Sartorius AG, Goettingen,
Germany). We also subcloned the cDNAs into pCMVhygro
which encodes the hygromycin resistance gene downstream of an
IRES to yield pCMVhygro-rHER-2ECD and pCMVhygro-hHER-
2ECD. These plasmids were transfected into CHO cells and stable
transfectants were selected using 250 mg/ml of hygromycin
(Roche Diagnostics, Mannheim, Germany) and then cloned by
limited dilution. CHO cells expressing high levels of HER-2 ECD
were identified by Western blot of culture supernatants. Similar to
the 293T-derived HER-2 ECD, supernatants from CHO cells
expressing high-levels of HER-2 ECD were concentrated by
centrifugation on Vivaspin 50000 columns (Sartorius AG,
Goettingen, Germany).
Western blotting
Recombinant HER-2 proteins from the 293T cultures were
mixed with gel-loading buffer. For some experiments, the proteins
were also treated with b-mercaptoethanol. The proteins were
electrophoresed through 10% SDS-PAGE, transferred onto
nitrocellulose membrane and probed with mouse sera diluted
1:1000. Bound antibody was detected using goat anti-mouse IgG
conjugated with HRP (Jackson Immunoresearch Laboratories Inc.
West Grove, Pennsylvania, USA) and the ECL chemiluminescent
reagent (Amersham Biosciences, NJ, USA). As positive controls for
HER-2 detection, we employed a monoclonal antibody against rat
HER-2 (BD Biosceinces, catalog# 610161) and a polyclonal
serum against human HER-2 (R&D Systems, catalog #AF1129)
Measurement of HER-2 specific antibodies by ELISA
96 well plates (Nunc, New York, USA) were coated with rat
HER-2 produced from the CHO cultures. Wells were blocked
with 5% non-fat milk in Tris-buffered saline (TBS, pH 7.4), and
reacted with serial dilutions (in TBS/0.5% non-fat milk) of mouse
sera. The signal was developed with substrate Sigmafast OPD
(Sigma Aldrich, St. Louis, USA) after incubation with goat anti-
mouse IgG conjugated with HRP.
Table 3. Occurrence of statistically significant amino acid pairs within mimotope collections.
HER-2ECD
a mimotopes HER-2FL mimotopes HER-2TUBO mimotopes
Generalized Amino
Acid Pairs
b
Occurrence within
mimotope collection
c
Generalized Amino
Acid Pairs
Occurrence within
mimotope collection
Generalized Amino
Acid Pairs
Occurrence within
mimotope collection
MH
d 11 OO 10 OY 2
JO 8 OP 9 PA 2
OP 8 GJ 7 AX 2
BJ 7 OJ 7 OH 2
HO 7 AG 5 BP 2
JP 6 ZY 5 HP 2
BP 5 GG 5 PP 2
HJ 5 PB 5 MX 1
OM 5 GZ 4 PM 1
AX 4 JZ 4 MP 1
XM 4 PP 4
XA 4 JH 3
JA 4 XX 3
GM 2 PM 2
HX 2
ZY 2
AH 2
aPolyserum used for mimotope isolation.
bSingle letters amino acid codes (See Methods).
cNumber of mimotopes carrying this generalized pair within the specific collection.
dUnique pairs are presented in bold, pairs shared by two datasets are presented in italics.
doi:10.1371/journal.pone.0005309.t003
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10
6 TUBO cells, which express high levels of rat HER-2, were
incubated with serial dilutions of mouse sera. The TUBO cells
were then washed to remove free mouse antibodies and incubated
with goat anti-mouse IgG conjugated with phycoerethrin (PE)
((Jackson Immunoresearch Laboratories Inc. West Grove, Penn-
sylvania, USA). Fluorescence intensity was measured using an
LSRII flow cytometer (BD Biosciences). MFI was calculated on a
minimum of 10000 events.
Phage display library screening
We employed a phage display library presenting random
peptides with the structure XC(X)10CX inserted into N-terminus
of pVIII, a major coat protein of filamentous bacteriophage,
Figure 3. Three-dimensional modeling of putative epitopes. Three-dimensional model of rat HER-2 is presented in two orientations. A.
clusters found for HER-2FLserum, B. clusters found for HER-2ECD-serum, C. clusters found for HER-2TUBO –serum. Serum- specific clusters of amino acid
pairs are numbered. Amino acid are coloured according to RasMol amino acid colour code: red=Glu and Asp, blue=Arg and Lys, brown=Pro,
orange=Ser and Thr, Cyan=Asn and Gln, violet=Trp and Phe, purple=His.
doi:10.1371/journal.pone.0005309.g003
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Cluster # Amino acids Cluster # Amino acids Cluster # Amino acids
ECD#1 98–100, 113, 135, 138, 162 FL#1 137–138, 164–169 TUBO#1 246, 248–249, 252,
260–264
ECD#2 86–90, 155–157, 159–160 FL#2 172–173, 175–176, 179
ECD#3 336–338, 359, 361, 363–366, 369–370 FL#3 336–338, 359, 361–363, 365–367, 370, 372–
373
ECD#4 1, 26, 29, 445, 466–471 FL#4 32, 35–36, 50–51, 53–57, 59, 73, 75–76, 84,
467–468
ECD#5 474–475, 477, 480–482 FL#5 284–286, 289,291, 295–299, 311–312
ECD#6 249, 252, 259–263, 265 FL#6 323, 326–328, 331
doi:10.1371/journal.pone.0005309.t004
Figure 4. Three-dimensional modeling of predicted epitopes and non-conserved amino acids. A. Epitopes predicted by the DiscoTope
method. Immunodominant epitopes are coloured in red, epitopes of lower immunogenicity are shown in yellow. B. Map reveals surface exposed
amino acids on the rat HER-2 extracellular domain that differ from the corresponding residues on mouse HER-2. Amino acid are coloured according to
RasMol amino acid colour code: red=Glu and Asp, blue=Arg and Lys, brown=Pro, orange=Ser and Thr, Cyan=Asn and Gln, violet=Trp and Phe,
purple=His.
doi:10.1371/journal.pone.0005309.g004
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Scott, Simon Fraser University) [38]. Screening of the phage
library was performed according to the method described by
Smith [39]. The library was initially depleted of phages recognized
by naı ¨ve mouse serum by 3 sequential pannings of the library with
immobilized serum of non-immunized mice. The resultant
‘‘depleted’’ library was used for mimotope identification. Similarly,
the sera obtained from immunized mice were initially depleted of
anti- phage activity by overnight incubation at 4uC with wild type
phage immobilized on plastic plates. The sera were also depleted
of IgM by similar incubation with immobilized anti-IgM antibody.
Serum specific peptides were selected by two rounds of iterative
affinity selection and specificity of phages for different mouse sera
was assessed by dot blot (according to the method described in
[40]). Briefly, phages were immobilized onto nitrocellulose
membranes. The membranes were then blocked with 5%
non-fat milk in TBS and probed with depleted mouse sera
(1:1000 in TBS/0.5% non-fat milk). Bound antibodies were
detected using goat anti-mouse IgG conjugated with HRP and the
ECL chemiluminescent reagent. DNAs from the serum-specific
phages were subsequently purified and the pVIII inserts were
sequenced and translated to amino acids for further analysis.
Computer algorithm
Amino acid sequences of affinity-selected phages were used as a
database for the computer algorithm [9,11] to perform a cluster
analysis. The algorithm is based on the assumption that affinity-
selected peptides must share key contact residues with the true
epitopes in the native protein. In the three-dimensional structure
of a protein, amino acids creating the epitope can be discontinuous
and become juxtaposed at the surface of the antigen through
protein folding. Therefore, we assume that neighboring amino
acids within the selected phage-displayed peptides may represent
pairs of juxtaposed amino acids residues on the protein surface. All
conserved residues were consolidated into six functional subgroups
of amino acids and given single-letter codes: Arg, Lys=B; Glu,
Asp=J; Ser, Thr=O; Leu, Ile, Val=U; Asn, Gln=X; Trp,
Phe=Z. Additionally, we assume that the most frequently
observed tandem amino acid pairs within a given set of affinity-
selected peptides likely represent the contact amino acids within
the epitope. The computer algorithm was used to find clusters of
these pairs on a surface of HER-2 protein by analyzing its three-
dimensional model. Three-dimensional models of HER-2 were
created by RasMol software (http://www.bernstein-plus-sons.
com/software/rasmol/doc/rasmol.html).
To corroborate the predictive power of our strategy, we also
employed the DiscoTope software [41] which predicts antibody
epitopes based on ‘‘a combination of amino acid statistics, spatial
information, and surface exposure’’. It is created on the basis of a
compiled data set from 76 X-ray structures of antibody/antigen
protein complexes.
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